hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06313541 id: 2024-Lung-LDRT/SBRT briefTitle: Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy overallStatus: NOT_YET_RECRUITING date: 2024-03-10 date: 2025-06-30 date: 2025-12-31 date: 2024-03-15 date: 2024-03-15 name: Fudan University class: OTHER briefSummary: This study is a multicenter, randomized controlled clinical trial to explore the preliminary efficacy and safety of treatment response adapted hybrid radiotherapy (LDRT and SBRT) in the first-line treatment of immunotherapy combined with chemotherapy for advanced driver-gene negative NSCLC, and to provide new ideas for the comprehensive treatment of advanced NSCLC conditions: NSCLC Stage IV studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 146 type: ESTIMATED name: SBRT or LDRT name: PD-1/PD-L1 inhibitor combined with platinum-based chemotherapy measure: Progression Free Survival measure: Overall Survival measure: Objective response rate measure: Progression free survival 2 measure: Treatment-related adverse event sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fudan University Shanghai Cancer Center city: Shanghai country: China lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06313528 id: 18726 id: J1I-MC-GZBW type: OTHER domain: Eli Lilly and Company briefTitle: A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943 overallStatus: RECRUITING date: 2024-03-20 date: 2025-07 date: 2025-07 date: 2024-03-15 date: 2024-04-19 name: Eli Lilly and Company class: INDUSTRY briefSummary: The main purpose of the study is to look at the effect of the study drug compared to placebo on calorie intake, energy metabolism, and appetite. The study will last up to 6 months and may include up to 20 visits. conditions: Obesity studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Sponsor-blind whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 74 type: ESTIMATED name: LY3437943 name: Placebo measure: Change from Baseline in Total Calorie Intake at Lunch and Dinner (Combined) measure: Change from Baseline in Sleep Metabolic Rate (SMR) measure: Change from Baseline in SMR measure: Change from Baseline in 24-hour Energy Expenditure (EE) measure: Change from Baseline in 24-hour EE measure: Change from Baseline in Total Calorie Intake at Lunch measure: Change from Baseline in Total Calorie Intake at Dinner measure: Change from Baseline in Fasting Appetite Visual Analog Score (VAS) sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: AdventHealth Orlando status: RECRUITING city: Orlando state: Florida zip: 32804 country: United States role: CONTACT phone: 407-303-7100 name: Steven Smith role: PRINCIPAL_INVESTIGATOR lat: 28.53834 lon: -81.37924 facility: Pennington Biomedical Research Center status: RECRUITING city: Baton Rouge state: Louisiana zip: 70808 country: United States role: CONTACT phone: 225-763-3000 name: Eric Ravussin role: PRINCIPAL_INVESTIGATOR lat: 30.45075 lon: -91.15455 facility: Columbia University Medical Center status: RECRUITING city: New York state: New York zip: 10032 country: United States role: CONTACT phone: 212-305-9949 name: Michael Rosenbaum role: PRINCIPAL_INVESTIGATOR lat: 40.71427 lon: -74.00597 hasResults: False
nctId: NCT06313515 id: STUDY00019529 briefTitle: Transcutaneous Spinal Cord Stimulation Combined With Arm Bike for Cardiovascular Recovery in SCI overallStatus: RECRUITING date: 2024-04-01 date: 2026-02-01 date: 2027-02-01 date: 2024-03-15 date: 2024-03-19 name: University of Washington class: OTHER briefSummary: Spinal cord injury (SCI) can make it hard for the body to self-regulate some of its automatic functions like blood pressure, breathing, and heart rate. This can also make it hard for those living with SCI to exercise or complete their usual daily activities. The goal of this randomized trial is to test combinatory therapy of moderate arm-crank exercise paired with non-invasive transcutaneous spinal cord stimulation (tSCS) for cardiovascular recovery in adults aged 21-65 following chronic motor-complete spinal cord injury (SCI) at or above the thoracic sixth spinal segment (≥T6).
Researchers will compare those who receive tSCS and do moderate arm-crank exercise to those who receive a sham stimulation and do moderate arm-crank exercise to see if tSCS is effective at improving cardiovascular and autonomic functioning in those with SCI. conditions: Spinal Cord Injuries studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: randomized, single-blind, sham-controlled trial with two arms (tSCS paired with arm-crank exercise compared to sham stimulation with exercise). Participants will be randomized into either the intervention or sham stimulation arm. Those in the sham arm only will initially receive sham stimulation, but then cross over to receive the active treatment arm, such that by the end all participants will have been exposed to the tSCS. tSCS participants will not receive sham stimulation. primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 16 type: ESTIMATED name: Transcutaneous Spinal Cord Stimulation name: Arm-crank bike exercise name: Sham Stimulation measure: Change in systolic Blood Pressure (BP) from baseline. measure: Change in systolic Blood Pressure during a sit-up test or head-up tilt test. measure: Heart rate variability recorded by electrocardiogram (ECG). measure: Peak oxygen uptake (VO2peak) measure: Autonomic dysfunction following Spinal Cord Injury (ADFSCI) measure measure: International Standards for Neurological Classification of Spinal Cord Injury measure: International Standards to document remaining Autonomic Function after Spinal Cord Injury (ISAFSCI) measure: Blood Pressure variability measure: Change from baseline- Graded Redefined Assessment of Strength, Sensation, and Prehension version 2 measure: Change from baseline- Capabilities of Upper Extremity Test measure: International Spinal Cord Injury Pain Basic Dataset version 2.0 measure: International Spinal Cord Injury Lower Urinary Tract Function Dataset measure: International Spinal Cord Injury Bowel Function Dataset sex: ALL minimumAge: 21 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Washington status: RECRUITING city: Seattle state: Washington zip: 98195 country: United States name: Soshi Samejima, DPT, PhD role: CONTACT lat: 47.60621 lon: -122.33207 hasResults: False
nctId: NCT06313502 id: 274271 briefTitle: High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2027-04 date: 2028-04 date: 2024-03-15 date: 2024-03-15 name: University of Arkansas class: OTHER name: University of Iowa briefSummary: The purpose of this research is to evaluate whether HDAA in combination with a single dose of 100 mg/m2 IV melphalan followed by autologous stem cell transplantation (ASCT) is safe and effective for subjects with relapsed refractory multiple myeloma. The proposed melphalan dose is 50% of the current standard myeloablative dose (200 mg/m2). Based on our preclinical data, the investigator hypothesize that the combination of reduced dose melphalan with IV HDAA will have high efficacy and tolerability
5. Determine oxidative stress parameters in plasma during treatment. conditions: Plasma Cell Disorder studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 18 type: ESTIMATED name: 75gm HDAA name: 100gm HDAA name: 125gm HDAA measure: Tumor Response measured by IMWG criteria measure: Safety and Tolerability of HDAA with reduced dose melphalan measured using number and severity of AEs measure: Rate of Minimal Residual Disease (MRD) negativity using 8 color flow cytometry measure: Determine quality of life parameter using QLQ-C30 measure: Determine quality of life parameter using EQ-5D-5L sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06313489 id: 282151 briefTitle: Rupture of Thumb's Long Extensor Tendon After Fracture of the Distal Radius, Study of Muscle and Tendon Pathology overallStatus: ACTIVE_NOT_RECRUITING date: 2023-02-01 date: 2023-12-31 date: 2024-06-30 date: 2024-03-15 date: 2024-03-15 name: Sahlgrenska University Hospital, Sweden class: OTHER briefSummary: Fractures of the wrist (fractures of the distal radius) are one of the most common fractures with almost 60 000 injuries per year in Sweden. One known complication following these fractures is that the long extensor tendon of the thumb ruptures (extensor pollicis longus tendon, EPL tendon). This leads to disability to stretch the thumb in order to grip bigger objects. Earlier studies show that the tendon ruptures in about 3-5% of all wrist fractures. These ruptures occur some weeks to months after the fracture.
The investigators plan to include in the study all patients that would get operated for an EPL tendon rupture after a fracture of the distal radius at the institution the study is conducted. After oral and written information to the patient and written consent the investigators will take some samples from the ruptured tendon and muscle for microscopical analysis. conditions: Distal Radius Fractures conditions: Tendon Injury - Hand conditions: Pathology studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 13 type: ACTUAL name: Biopsy of EPL tendon and muscle during the operation measure: Histopathological analysis of the EPL muscle measure: Histopathological analysis of the EPL tendon sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sahlgrenska University Hospital city: Gothenburg state: Västra Götaland zip: 43180 country: Sweden lat: 57.70716 lon: 11.96679 hasResults: False
nctId: NCT06313476 id: SYSKY-2024-030-01 briefTitle: AMH Predicts Postchemotherapy Menopause in Premenopausal Breast Cancer Patients overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2026-04-30 date: 2026-04-30 date: 2024-03-15 date: 2024-03-15 name: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University class: OTHER briefSummary: To determine the accuracy of AMH postchemotherapy in predicting permanent menopause after chemotherapy in breast cancer patients who did not use OFS before menopause conditions: Breast Cancer studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 153 type: ESTIMATED measure: Anti-Mullerian Hormone measure: Estradiol measure: Follicle Stimulating Hormone measure: Menstruation sex: FEMALE minimumAge: 40 Years maximumAge: 59 Years stdAges: ADULT hasResults: False
nctId: NCT06313463 id: SYSKY-2023-1282-02 briefTitle: Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy overallStatus: RECRUITING date: 2024-03 date: 2031-09 date: 2035-12 date: 2024-03-15 date: 2024-03-15 name: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University class: OTHER briefSummary: This study aims to evaluate the efficacy and safety of camrelizumab in combination with capecitabine compared to placebo in combination with capecitabine as adjuvant therapy for patients with triple-negative breast cancer (TNBC) who have not achieved pathological complete response (pCR) after neoadjuvant chemotherapy and have tertiary lymphoid structures (TLS) in the tumor tissue. The primary endpoint of this study is disease-free survival (DFS) to assess the long-term effectiveness of the treatment. Secondary endpoints include invasive disease- free survival (IDFS), overall survival (OS), distant recurrence-free interval (DRFI), as well as safety and patient-reported outcomes. These endpoints will comprehensively evaluate the effectiveness of the treatment and the overall survival status of the patients.
The study anticipates a total sample size of 375 patients, who will be randomly assigned to either the experimental group or the control group. The experimental group will receive 8 cycles of adjuvant therapy of capecitabine and camrelizumab. The control group will receive 8 cycles of adjuvant therapy with capecitabine and placebo. This study aims to investigate whether non-pcr breast cancer patients with TLS in tumors can benefit from the adjuvant immunotherapy. conditions: Breast Neoplasms studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 375 type: ESTIMATED name: Carrellizumab + Capecitabine name: Placebo + Capecitabine measure: Disease-Free Survival measure: Invasive Disease-Free Survival measure: Overall Survival measure: Distant Recurrence-Free Interval measure: Patient-reported outcomes-Proportion of patients in each group experiencing clinically meaningful deterioration measure: Patient-reported outcomes-EORTC QLQ-C30 scores after treatment measure: Patient-reported outcomes-EORTC QLQ-C30 scores changes sex: FEMALE minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sun Yat-sen Memorial Hospital, Sun Yat-sen University status: RECRUITING city: Guangzhou state: Guangdong zip: 510120 country: China name: Shicheng Su, M.D., Ph.D. role: CONTACT phone: +86 13632394954 email: lnl_trial@126.com name: Erwei Song, M.D., Ph.D. role: CONTACT phone: +86 13719237746 email: lnl_trial@126.com lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06313450 id: B2023-110-X02 briefTitle: De-escalated Radiotherapy for Primary Tumor After Neoadjuvant Therapy With Toripalimab Plus Chemotherapy for Nasopharyngeal Carcinoma overallStatus: RECRUITING date: 2024-03-04 date: 2026-02-01 date: 2028-02-01 date: 2024-03-15 date: 2024-03-19 name: Sun Yat-sen University class: OTHER briefSummary: In the IMRT era, patients with stage II-III (AJCC8th) nasopharyngeal carcinoma achieve high local control. However, survivors are increasingly experiencing late radiation-induced toxicities. A previous study found that reducing the radiation dose to the primary site to 60Gy for patients who achieved partial or complete response to induction chemotherapy resulted in a lower rate of late toxicities and an inferior local control rate. The investigators aim to reduce the radiation dose to the primary site for patients after immunochemotherapy, given the potential of neoadjuvant chemotherapy and immunotherapy to increase response rates and long-term survival. The protocol includes participants with stage II-III (AJCC8th), except T2N0M0, to receive three courses of neoadjuvant gemcitabine plus cisplatin and Toripalimab. If the primary tumour regresses by over 75%, de-escalated radiotherapy with 60Gy will be administered, and participants will receive two cycles of cisplatin and three cycles of Toripalimab during the radiotherapy course. Otherwise, participants will receive conventional radiotherapy and concurrent chemotherapy with cisplatin for two cycles as usual. The aim of this study is to investigate the 3-year local control rate and toxicities of de-escalated radiotherapy. conditions: Nasopharyngeal Carcinoma conditions: Radiotherapy; Complications conditions: IMMUNOTHERAPY studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 112 type: ESTIMATED name: de-escalated radiotherapy name: conventional radiotherapy measure: local recurrence rate(LRR) measure: primary tumor volume regression≥75% rate measure: 3-year overall survival measure: acute and late radiation-induced toxicities measure: complete response rate of primary tumor sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sun Yat-Sen University Cancer Center status: RECRUITING city: Guangzhou state: Guangdong zip: 510060 country: China name: Puyun Ouyang role: CONTACT phone: +8602087342926 email: ouyangpy@sysucc.org.cn name: Fangyun Xie role: PRINCIPAL_INVESTIGATOR lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06313437 id: 24-021 briefTitle: Revumenib in Combination With 7+3 + Midostaurin in AML overallStatus: NOT_YET_RECRUITING date: 2024-09 date: 2026-03-02 date: 2027-03-02 date: 2024-03-15 date: 2024-03-21 name: Maximilian Stahl, MD class: OTHER name: Syndax Pharmaceuticals briefSummary: This research is being conducted to determine a safe and effective dose of revumenib that can be given in combination with standard induction (initial therapy to induce a remission) + FLT3 targeted therapy (midostaurin) and a single cycle of post-remission therapy + FLT3 targeted therapy (midostaurin) to participants with newly diagnosed Nucleophosmin (NPM1) and FMS-like tyrosine kinase 3 (FLT3) mutated Acute Myeloid Leukemia (AML).
* Daunorubicin (a type of antineoplastic agent) conditions: Acute Myeloid Leukemia conditions: AML, Adult conditions: AML With Gene Mutations conditions: AML conditions: Leukemia studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 22 type: ESTIMATED name: Revumenib name: Midostaurin name: Cytarabine name: Daunorubicin measure: Number of Participants Experiencing Dose Limiting Toxicity (DLT) measure: Maximum Tolerated Dose (MTD) measure: Recommended phase II dose (RP2D) measure: Complete Remission (CR) rate with induction chemotherapy measure: Complete Remission (CR) rate with consolidation chemotherapy measure: Flow Measurable Residual Disease Negative (MRD-) rate with induction chemotherapy measure: Flow Measurable Residual Disease Negative (MRD-) rate with consolidation chemotherapy measure: Molecular Measurable Residual Disease Negative (MRD-) rate with induction chemotherapy measure: Molecular Measurable Residual Disease Negative (MRD-) rate with consolidation chemotherapy measure: Relapse-Free Survival at 1 year (RFS1) measure: Overall Survival at 1 year (OS1) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Brigham and Women's Hospital city: Boston state: Massachusetts zip: 02215 country: United States lat: 42.35843 lon: -71.05977 facility: Dana-Farber Cancer Institute city: Boston state: Massachusetts zip: 02215 country: United States lat: 42.35843 lon: -71.05977 hasResults: False
nctId: NCT06313424 id: 9029 briefTitle: Arthroscopic Treatment of Meniscal Lesions on Healthy Meniscus in Children and Adolescents acronym: ATML overallStatus: RECRUITING date: 2023-08-29 date: 2024-04 date: 2024-04-29 date: 2024-03-15 date: 2024-03-15 name: University Hospital, Strasbourg, France class: OTHER briefSummary: Meniscal lesions are common in pediatrics and mainly affect adolescents. These lesions can jeopardize the functional prognosis of the knee in the short, medium or long term if they are not well managed.
The treatment of meniscal lesions comes down to either conservative or restorative treatment or non-conservative treatment by meniscectomy. For most authors, the treatment of meniscal lesions must remain restorative through meniscal suture, leaving no room for meniscectomy. The open approach has given way to the arthroscopic approach which, according to the literature, is the gold standard. Meniscal lesions are varied and therefore there are numerous therapeutic procedures. Therapeutic indications are precise but the results of the treatments remain differently assessed depending on the studies; studies evaluating the results of treatment in the pediatric population are few in number.
Based on this observation, the present study aims to describe the results of repairs of meniscal lesions in pediatric traumatology. conditions: Knee Injuries studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 120 type: ESTIMATED measure: description of the results of repairs of meniscal lesions in pediatric traumatology sex: ALL minimumAge: 1 Year maximumAge: 17 Years stdAges: CHILD facility: Service de Chirurgie Pédiatrique - CHU de Strasbourg - France status: RECRUITING city: Strasbourg zip: 67091 country: France name: Philippe GICQUEL, MD, PhD role: CONTACT phone: 33 3 88 12 82 65 email: Philippe.Gicquel@chru-strasbourg.fr name: Philippe GICQUEL, MD, PhD role: PRINCIPAL_INVESTIGATOR name: Saïd Nahl Oumar GANAME, MD role: PRINCIPAL_INVESTIGATOR lat: 48.58392 lon: 7.74553 hasResults: False
nctId: NCT06313411 id: 8778 briefTitle: How do I Perform a Laparoscopic Removal of a Pelvic Retroperitoneal Schwannoma acronym: PRS overallStatus: RECRUITING date: 2022-11-23 date: 2024-04 date: 2024-04 date: 2024-03-15 date: 2024-03-15 name: University Hospital, Strasbourg, France class: OTHER briefSummary: Schwannomas are mainly benign tumors, which develop mainly in the skull or in the cervical region. Retroperitoneal location is rare, since it represents between 0.5 and 5% of scwhanomas. The malignant retroperitoneal form is, however, more common than in other locations.
Acquiring the surgical techniques and skills necessary to carry out these types of procedures is essential to providing optimal patient care. conditions: Endometriosis Pelvic studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: RETROSPECTIVE count: 1 type: ESTIMATED measure: laparoscopic removal of a retroperitoneal pelvic schwannoma sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Service de Gynécologie Obstétrique - CHU de Strasbourg - France status: RECRUITING city: Strasbourg zip: 67091 country: France name: Emilie FALLER, MD role: CONTACT phone: 33 3 88 12 63 87 email: emilie.faller@chru-strasbourg.fr name: Alexandre PIFFER, MD role: CONTACT phone: 33 6 71 47 38 61 email: Alexandre.piffer@yahoo.fr name: Emilie FALLER, MD role: PRINCIPAL_INVESTIGATOR name: Alexandre PIFFER, MD role: SUB_INVESTIGATOR lat: 48.58392 lon: 7.74553 hasResults: False
nctId: NCT06313398 id: 10001883 id: 001883-H briefTitle: Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling overallStatus: RECRUITING date: 2024-05-01 date: 2029-05-01 date: 2029-06-15 date: 2024-03-15 date: 2024-04-26 name: National Heart, Lung, and Blood Institute (NHLBI) class: NIH name: Children's National Research Institute briefSummary: Background:
Sickle cell disease (SCD) is an inherited disorder of the blood. SCD causes red blood cells (RBCs) to die early. This can lead to a shortage of healthy cells. SCD and other blood disorders can be managed with drugs or cured with a bone marrow transplant. Researchers want to know how long RBCs survive in people with SCD and other blood disorders before and after treatment compared to those who had a bone marrow transplant.
Participants will return regularly to have smaller blood samples (about 2 teaspoons) drawn. These samples will be tested to detect the percentage of cells that have biotin labels. These visits may be every 2 weeks, 4 weeks, or some other interval. Participants will continue this schedule for up to 20 weeks or until biotin can no longer be detected.... conditions: Sickle Cell Disease conditions: Thalassemia conditions: Hemoglobinopathy studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 100 type: ESTIMATED name: Biotin-labeled red blood cells measure: To determine and compare red blood cell survival, by virtue of the mean number of days of detectable biotin-labeled RBCs, in participants with SCD and/or other hemoglobinopathies. measure: Validate the association of RBC survival with known markers of increased survival. sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National Institutes of Health Clinical Center status: RECRUITING city: Bethesda state: Maryland zip: 20892 country: United States name: NIH Clinical Center Office of Patient Recruitment (OPR) role: CONTACT phone: 800-411-1222 phoneExt: TTY dial 711 email: ccopr@nih.gov lat: 38.98067 lon: -77.10026 hasResults: False